Nearly 4,500 cases were pulled from shelves in 23 states after it was found that the affected cans had been mislabeled.

The US Food and Drug Administration has cleared the first-ever blood test for diagnosing Alzheimer's disease, offering a less invasive and simpler alternative for the millions of seniors facing cognitive decline.

It’s really important that we protect ... safe access to medication abortion no matter where people live — Virginia is playing a key role in the South right now," Whole Woman’s Health Alliance founder and president Amy Hagstrom Miller said Monday.

By Stephanie Brown HealthDay ReporterMONDAY, May 19, 2025 (HealthDay News) -- Last week, the U.S. Food and Drug Administration announced a move to improve transparency and strengthen the safety of chemicals used in the nation's food supply.

The FDA has granted 510(k) marketing clearance to the first in vitro blood-based biomarker diagnostic device for Alzheimer’s disease. Fujirebio’s Lumipulse G pTau217/ -Amyloid 1-42 Plasma Ratio was developed for the early detection of amyloid plaques associated with AD in adults aged 55 years and older who show signs of the condition,

Japan-based Fujirebio's test, which helps doctors diagnose Alzheimer's disease, is intended for patients with signs of cognitive decline.

FDA and the Department of Health and Human Services (HHS) have launched a public Request for Information (RFI) to “identify and eliminate outdated or unnecessary regulations” in alignment with President Donald Trump’s Executive Order 14192.

US Food and Drug Administration Commissioner Marty Makary named agency veterans to lead tobacco regulation and inspections, two high-profile areas, according to documents seen by Bloomberg.